Gilteritinib

證據等級: L5

預測適應症: 10 個

Gilteritinib: From Relapsed/Refractory AML to Myelodysplastic/Myeloproliferative Disease

One-Sentence Summary

Gilteritinib (Xospata) is a highly selective FLT3/AXL kinase inhibitor approved internationally for relapsed or refractory FLT3-mutated acute myeloid leukemia (AML). The TxGNN model generates 10 candidate predictions for new indications; after filtering out biologically implausible high-scoring false positives, myelodysplastic/myeloproliferative disease (MDS/MPN) emerges as the most evidence-supported repurposing candidate, currently backed by 4 clinical trials and 1 publication, with an overall evidence level of L2 and a TxGNN score of 97.00%.

Note on top TxGNN prediction: The highest-ranked prediction (Rank 1: bulbar polio, score 99.10%) is flagged as a biologically implausible false positive — the disease mechanism (enteroviral lower motor neuron infection) has no known connection to FLT3/AXL signaling, and the evidence pack itself identifies it as a likely knowledge-graph network artifact. This report focuses on the highest-quality actionable prediction.

Quick Overview

Item	Content
Original Indication	Relapsed/refractory FLT3-mutated acute myeloid leukemia (AML)
Predicted New Indication	Myelodysplastic/Myeloproliferative Disease (MDS/MPN)
TxGNN Prediction Score	97.00% (Rank #10 among 10 candidates)
Evidence Level	L2
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack. Based on established pharmacological knowledge, Gilteritinib is a highly selective inhibitor of FLT3 (FMS-like tyrosine kinase 3) and AXL receptor tyrosine kinase. It works by binding to both the FLT3-ITD (internal tandem duplication) and FLT3-TKD (tyrosine kinase domain point mutation) variants, blocking downstream proliferative and anti-apoptotic signaling in FLT3-dependent leukemic cells. This dual FLT3/AXL inhibition distinguishes it from first-generation FLT3 inhibitors such as midostaurin.

MDS/MPN overlap syndromes — including chronic myelomonocytic leukemia (CMML), atypical CML (aCML), and MDS/MPN-unclassifiable — share key molecular features with AML. FLT3 mutations (FLT3-ITD, FLT3-TKD) and FLT3 gene fusions such as ETV6-FLT3 are recognized driver events in this disease group, conferring dependence on FLT3 signaling for clonal proliferation. The mechanistic rationale for Gilteritinib in FLT3-positive MDS/MPN therefore follows directly from its established AML biology.

Critically, MDS/MPN is biologically positioned on the continuum toward AML — many high-risk MDS/MPN cases eventually transform to overt AML. Gilteritinib has already been evaluated directly in combination with azacitidine and venetoclax in a Phase I/II trial (NCT04140487) that explicitly enrolls high-risk MDS/MPN patients alongside AML cases, providing the most direct clinical precedent available. A published case report (PMID 33792628) further demonstrates ex vivo sensitivity of ETV6-FLT3 fusion-driven myeloid neoplasm to Type I FLT3 inhibitors, reinforcing the therapeutic target hypothesis.

Clinical Trial Evidence

Primary indication: Myelodysplastic/Myeloproliferative Disease (Rank #10)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04140487	Phase I/II	Recruiting	97	Azacitidine + Venetoclax + Gilteritinib triple combination in FLT3-mutation-positive AML or high-risk MDS/MPN (recurrent or refractory); Gilteritinib is the central investigational drug — provides direct Phase I/II safety and preliminary efficacy data in this disease group
NCT03922100	Phase I/II	Terminated	63	NMS-03592088 (FLT3/KIT/CSF1R triple inhibitor) in R/R AML or CMML; validates FLT3 inhibition as a mechanism in MDS-spectrum disease; trial terminated — reasons (safety vs. commercial) should be reviewed before extrapolation
NCT05564390	Phase 2	Recruiting	2,000	NCI MyeloMATCH master screening and reassessment protocol; large platform trial for AML/MDS/MPN with FLT3 and other molecular biomarker stratification; provides a framework for FLT3-directed sub-studies, but Gilteritinib-specific sub-trial assignment requires confirmation
NCT02115295	Phase 2	Recruiting	508	Cladribine + Idarubicin + Cytarabine + Venetoclax in AML/high-risk MDS; no FLT3 inhibitor component — serves as chemotherapy comparator benchmark only

Additional — Radiation-related AML/MDS (Rank #3, L3)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05564390	Phase 2	Recruiting	2,000	MyeloMATCH protocol also covers radiation-related AML/MDS subtypes under its broad AML/MDS eligibility framework; indirect platform support only

Literature Evidence

Primary indication: Myelodysplastic/Myeloproliferative Disease (Rank #10)

PMID	Year	Type	Journal	Key Findings
33792628	2021	Case Report	Blood Advances	ETV6-FLT3 fusion-driven myeloid/lymphoid neoplasm with eosinophilia in an infant; patient-derived ex vivo studies demonstrated increased sensitivity to Type I FLT3 inhibitors compared to Type II inhibitors — directly supports FLT3 fusion as a therapeutic target in MDS/MPN-spectrum disease, and validates the mechanistic rationale for Gilteritinib (a Type I FLT3 inhibitor) in this indication

Singapore Market Information

Gilteritinib is currently not registered in Singapore. There are no active product authorizations on record.

Gilteritinib is not available through standard regulatory channels in Singapore. Any clinical use would require a Special Access Route (SAR) application or a compassionate use/clinical trial framework. This represents a key regulatory barrier that must be addressed before clinical deployment.

Cytotoxicity

Gilteritinib is an antineoplastic targeted therapy (FLT3/AXL tyrosine kinase inhibitor) indicated for leukemia treatment.

Item	Content
Cytotoxicity Classification	Targeted therapy — selective FLT3/AXL receptor tyrosine kinase inhibitor (small molecule, oral)
Myelosuppression Risk	Moderate — febrile neutropenia, anemia, and thrombocytopenia are recognized risks; differentiation syndrome (a potentially life-threatening complication unique to AML/MDS targeted therapies) has been reported
Emetogenicity Classification	Low to moderate
Monitoring Items	CBC with differential (weekly for first month, then regularly), liver function tests (ALT/AST/bilirubin), renal function, QTc interval (ECG before and during treatment), serum electrolytes (Mg²⁺, K⁺, Ca²⁺), signs and symptoms of differentiation syndrome (fever, dyspnea, pleural/pericardial effusion, rapid weight gain)
Handling Protection	Please refer to the package insert warnings and precautions for cytotoxic handling requirements

Safety Considerations

No safety data (key warnings, contraindications, or drug interaction profile) was available in this evidence pack. All safety fields are identified as data gaps.

Please refer to the full package insert (FDA prescribing information / EMA Summary of Product Characteristics) for safety information. Based on the drug class and published literature, clinicians should be particularly alert to: differentiation syndrome (potentially fatal, requires prompt corticosteroid treatment), QTc prolongation (avoid concurrent QT-prolonging agents), embryo-fetal toxicity (contraindicated in pregnancy), and posterior reversible encephalopathy syndrome (PRES). Detailed DDI data was not retrieved and should be assessed separately, especially for CYP3A4 interactions given the metabolic profile of kinase inhibitors.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Among the 10 TxGNN-predicted indications, myelodysplastic/myeloproliferative disease is the only candidate with direct mechanistic grounding (shared FLT3 signaling with the approved AML indication) and clinical trial support — most critically, NCT04140487 directly tests Gilteritinib in high-risk MDS/MPN patients, providing Phase I/II-level evidence for this repurposing direction. However, Singapore has no existing Gilteritinib registration, and safety documentation is currently unavailable, both of which must be resolved before clinical translation.

To proceed, the following is needed:

Blocking — Safety review: Retrieve full FDA label / EMA SmPC to complete the safety assessment; this is identified as a blocking data gap (DG001) and must be addressed before any clinical or regulatory step
High priority — MOA documentation: Formally document FLT3/AXL mechanism of action from DrugBank or published sources (DG002); essential for regulatory dossier and mechanistic justification
FLT3 mutation prevalence in MDS/MPN: Confirm FLT3-ITD/TKD mutation frequency in the specific MDS/MPN subtypes targeted (CMML, MDS/MPN-U, aCML) to define the eligible biomarker-selected patient population
Monitor NCT04140487: Obtain interim or published results from the Azacitidine + Venetoclax + Gilteritinib Phase I/II trial; this is the most directly relevant evidence source
Singapore regulatory pathway: Gilteritinib is not registered in Singapore; initiate a Special Access Route (SAR) or compassionate use application strategy, or plan a local Phase II trial
Biomarker stratification protocol: Establish FLT3 mutation testing (PCR or NGS-based) as a mandatory inclusion criterion for any prospective study

Summary of All 10 TxGNN Predictions

| Rank | Indication | TxGNN Score | Evidence Level | Decision | |------|-----------|:-----------:|:--------------:|---------| | 1 | Bulbar polio | 99.10% | L5 | Hold — biologically implausible (false positive) | | 2 | AML/MDS related to alkylating agent | 98.99% | L4 | Research Question — FLT3 mutation prevalence needs confirmation | | 3 | AML/MDS related to radiation | 98.99% | L3 | Research Question — indirect framework support only | | 4 | 5q35 microduplication syndrome | 98.89% | L5 | Hold — biologically implausible (gene dosage mechanism, no FLT3 link) | | 5 | Neuralgic amyotrophy | 98.10% | L5 | Hold — no mechanistic link to FLT3/AXL | | 6 | Amyotrophic neuralgia | 97.96% | L5 | Hold — likely ontology synonym of #5, same assessment | | 7 | Vertebral anomalies & T-cell dysfunction | 97.36% | L5 | Hold — no mechanistic basis | | 8 | Ganglioneuroblastoma | 97.22% | L5 | Hold — AXL hypothesis requires preclinical validation first | | 9 | Retroperitoneal neoplasm | 97.01% | L5 | Hold — diagnosis too broad; histological subtype must be defined | | 10 | Myelodysplastic/Myeloproliferative Disease | 97.00% | L2 | Proceed with Guardrails ✓ |

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.